Proactive Investors - Run By Investors For Investors

CytoDyn stock jumps as investor focus shifts to leronlimab as CymaBay flames out

Vancouver-based CytoDyn's fortunes rose as CymaBay Therapeutics Inc’s NASH ambitions hit a wall
A researcher in a lab
NASH is difficult to diagnose and there are currently no therapies approved by the FDA

CytoDyn Inc (OTCMKTS:CYDY) stock soared Tuesday as investors focused on its lead drug leronlimab in the Non-Alcoholic Steatohepatitis (NASH) space after CymaBay Therapeutics Inc’s (NASDAQ:CBAY) drug seladelpar posted disappointing results in a mid-stage clinical trial linked to NASH.  

NASH is liver inflammation and damage caused by a buildup of fat in the liver. Patients with this disease are often told they have a "fatty liver."

Last month, Vancouver, Washington-based CytoDyn said that the Cleveland Clinic will test its flagship drug leronlimab (PRO 14O) to determine if it can prevent NASH in mice.

CytoDyn stock closed 10.8% higher to $0.44 on the OTC Markets on Tuesday, even as shares in CymaBay tumbled 45.9% to $6.

READ: CytoDyn's flagship drug leronlimab to be tested to prevent fatty liver diease in mice

The goal of CytoDyn’s exploratory pre-clinical studies by Dr Daniel Linder is to establish leronlimab’s ability to prevent the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) into NASH.

In a separate development, Newark, California-based CymaBay which had enrolled 181 patients with moderate NASH, and treated them for 12 weeks, suffered a setback.

In CymaBay’s Phase 2 study, three oral doses of seladelpar, all performed worse than a harmless placebo, based on a non-invasive imaging test that measures decreases in liver fat.

READ: CymaBay stock bombs after seladelpar disappoints in a study for its liver treatment

If left untreated, NASH can progress to more serious disease stages, such as advanced fibrosis, cirrhosis, liver failure or liver cancer. CytoDyn said the disease is expected to become the leading cause of liver transplants by 2020.

Despite the growing awareness of NASH, it remains difficult to diagnose and there are currently no therapies approved by the US Food and Drug Administration.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

 

View full CYDY profile View Profile

CytoDyn Timeline

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
patch
May 20 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use